BioCryst submits peramivir NDA

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) submitted an NDA to FDA for peramivir to treat acute uncomplicated influenza in adults. The IV viral neuraminidase inhibitor is being developed under a contract with HHS's Biomedical Advanced Research and Development Agency (BARDA). Peramivir is approved in Japan and Korea to treat influenza. Shionogi & Co. Ltd. (Tokyo:4507; Osaka:4507) has Japanese and Taiwanese rights to peramivir from BioCryst. Green Cross Corp. (Yongin-si, South Korea) has South Korean rights. ...